<?xml version="1.0" encoding="UTF-8"?>
<p id="par0015">Immune or convalescent plasma collected from people who have fully recovered from infection contains antibodies against the infectious agent. Convalescent plasma provides passive immunity and has been used for the prophylaxis and treatment of a number of infectious diseases, including recent epidemics with SARS-Cov-1, Ebola and Middle Eastern Respiratory Syndrome (MERS) [
 <xref rid="bib0005" ref-type="bibr">1</xref>]. Small studies from China have demonstrated that infusion of convalescent plasma from people who have recovered from COVID-19 is safe and results in reduction of viral load and improved clinical outcome. This prompted the FDA to allow the use of convalescent plasma in patients with COVID-19 [
 <xref rid="bib0005" ref-type="bibr">1</xref>]. The proposed infusion dose is 200â€‰ml of plasma. However, this is based on the Chinese experience alone and deserves further study.
</p>
